The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.
Age 40 years and older
Subjects who have mild to moderate Open Angle Glaucoma (OAG)
Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation > 3 months prior to screening and within the last 2 years
Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)
History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation
Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery
Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome
Severe Open Angle Glaucoma